Ardsley Advisory Partners’s Regenxbio RGNX Stock Holding History

Ardsley Advisory Partners’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,000	Closed	-$344K	–	172
2019 Q1	$344K	Buy	+6,000	New	+$297K	0.07%	98
2018 Q2	–	Sell	-7,500	Closed	-$224K	–	176
2018 Q1	$224K	Sell	7,500 -2,500	-25%	-$72.8K	0.03%	136
2017 Q4	$334K	Hold	10,000	–	–	0.04%	106
2017 Q3	$330K	Hold	10,000	–	–	0.04%	108
2017 Q2	$197K	Buy	+10,000	New	+$194K	0.03%	129

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ardsley Advisory Partners's RGNX Position: Q2 2019 in Review

Ardsley Advisory Partners sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 6,000 shares — an estimated $344K sold.

Ardsley Advisory Partners first reported a position in RGNX in Q2 2017 and held it in 5 quarters. The position peaked at $344K in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

Ardsley Advisory Partners reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
Ardsley Advisory Partners sold 6,000 Regenxbio shares in Q2 2019, an estimated $344K.
Ardsley Advisory Partners first reported a position in Regenxbio in Q2 2017 and held it in 5 quarters.
Ardsley Advisory Partners's Regenxbio position peaked at $344K in Q1 2019.
186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Ardsley Advisory Partners's 13F filing for Q2 2019, filed 13 Aug 2019.